73 Results for "

PLGA

" in MedChemExpress (MCE) Product Catalog:
Products (73)

73 Results for "PLGA" in MCE Product Catalog:

32
32 Publications Verification
Cat. No.: HY-B2247
CAS No.: 34346-01-5
Synonyms: poly(lactic-co-glycolic acid) (50:50)
PLGA (50:50) (poly(lactic-co-glycolic acid) (50:50)) is a copolymer of poly lactic acid (PLA) and poly glycolic acid (PGA) which can be used to fabricate devices for drug delivery and tissue engineering applications.
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-B2247A
CAS No.: 34346-01-5
Synonyms: poly(lactic-co-glycolic acid) (75:25)
Research Areas:  

Others

PLGA (75:25) is a low toxicity, biocompatible and biodegradable controlled drug delivery carrier, can achieve slow release in the organism. PLGA (75:25) is a copolymer of 75% poly lactic acid (PLA) and 25% poly glycolic acid (PGA). PLGA (75:25) has been extensively studied as delivery vehicles for agents, proteins and various other macromolecules such as DNA, RNA and peptides .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-Y0850O
CAS No.: 9002-89-5
Synonyms: PVA (Mw 31000-50000, 87-89% hydrolyzed); Poly(Ethenol) (Mw 31000-50000, 87-89% hydrolyzed)
Polyvinyl alcohol (PVA; Poly (Ethenol)) (Mw 31000-50000, 87-89% hydrolyzed) is a polymer with emulsifying and stabilizing properties, with a degree of hydrolysis of 87-89%. Polyvinyl alcohol (Mw 31000-50000, 87-89% hydrolyzed) mainly acts as a stabilizer in the preparation of nanomedicines; it not only maintains the structural integrity of PEGylated PLGA nanoparticles during double emulsion synthesis, but also facilitates the preparation of chitosan/matrine-PLGA nanoparticle aqueous solutions and lipid-polymer nanoparticles. Polyvinyl alcohol (Mw 31000-50000, 87-89% hydrolyzed) can be widely used in research related to fields such as breast cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W127512
CAS No.: 546-18-9
Target:  

Drug Intermediate

Research Areas:  

Others

5β-Cholanic acid is a hydrophobic modifier used to modify polymer carriers. 5β-Cholanic acid can improve the acid stability, cell penetration efficiency and drug sustained release ability of nanocarriers, and optimize the oral effectiveness of delivered molecules. 5β-Cholanic acid can covalently bind to Glycol chitosan (GC) to form a GC-CA conjugate, which optimizes the hydrophobic anchoring ability of nanoparticles and enables them to be stably adsorbed on the surface of PLGA nanoparticles. Such nanoparticles can resist dissociation in the gastric acid environment and maintain positive charge to enhance endocytic uptake by intestinal epithelial cells (such as Caco-2 cells). 5β-Cholanic acid can be used in the development of drug delivery systems .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-D0791
CAS No.: 95197-95-8
Synonyms: 5(6)-Tetramethylrhodamine isothiocyanate
TRITC (5(6)-Tetramethylrhodamine isothiocyanate) is a commonly used fluorescent dye, belonging to the Rhodamine derivative family. It exhibits red fluorescence properties (Ex/Em ≈ 550/580 nm). TRITC can be used for cell labeling and imaging .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-158089
Purity:  ≥95.0%
Research Areas:  

Others

PLGA-COOH (MW 80000) (LA/GA 50:50) is a copolymer composed of lactic acid (LA)-glycolic acid (GA) at a molar ratio of 50:50 and a terminal carboxyl group. PLGA-COOH (MW 80000) (LA/GA 50:50) is used in compound delivery systems due to its biocompatibility and biodegradability .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-148775B
Purity:  ≥95.0%
PLGA-PEG-MAL (20KDA-5.0KDA, LA:GA RATIO 40:60) is a biodegradable amphipathic polymeric nanocarrier of poly (lactic-co-glycolic acid)-block-poly (ethylene glycol) (PLGA-PEG-Mal) that allows covalent modification of functional molecules. PLGA-PEG-MAL (20KDA-5.0KDA, LA:GA RATIO 40:60) modified with Angiopep-2 can cross the blood-brain barrier and exhibits targeting selectivity for glioblastoma cells. PLGA-PEG-MAL (20KDA-5.0KDA, LA:GA RATIO 40:60) can capture tumor-derived protein antigens, and exerts immunomodulatory effects when conjugated with anti-OX40 antibody; when used in combination with A2-CL/Dbait nanoparticles and radiotherapy, it prolongs survival time and reduces tumor volume in glioblastoma mouse models. PLGA-PEG-MAL (20KDA-5.0KDA, LA:GA RATIO 40:60) can be used for studies related to bacterial wound infections and glioblastoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-176499
Research Areas:  

Others

PLGA38000-PEG10000 is an amphiphilic polymer. Amphiphilic polymers can be used in drug delivery studies due to their ability to self-assemble into discrete aggregates .
loading...
    loading...
Cat. No.: HY-W723152
CAS No.: 26780-50-7
Target:  

Drug Intermediate

Research Areas:  

Inflammation/Immunology

Poly(D,L-lactide-co-glycolide) is a biodegradable polymer copolymer. Poly(D,L-lactide-co-glycolide) undergoes degradation through ester bond hydrolysis into lactic acid and glycolic acid. These two products can be naturally eliminated through metabolism in the body (such as the tricarboxylic acid cycle), without the risk of long-term accumulation. Poly(D,L-lactide-co-glycolide) can be used in medical sutures, implants, and drug delivery systems .
loading...
    loading...
Cat. No.: HY-W440823A
CAS No.: 474922-26-4
Synonyms: DSPE-PEG1000-NH2 ammonium
DSPE-PEG1000-Amine (DSPE-PEG1000-NH2) ammonium is a 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol conjugate with a terminal amino group. DSPE-PEG1000-Amine ammonium can functionalize the surface of PLGA-lecithin-PEG core-shell nanoparticles to introduce positive surface charges. The amino group of DSPE-PEG1000-Amine ammonium can be converted into an aromatic aldehyde to react with the acetone-protected aromatic hydrazide on the surface of bovine carbonic anhydrase (BCA) molecules .
loading...
    loading...
Cat. No.: HY-P10646
CAS No.: 2896181-32-9
Research Areas:  

Neurological Disease

Muscle homing peptide M12 can preferentially bind to surface protein of muscle cells. Muscle homing peptide M12 mediates enhanced cellular uptake of nanoparticles (NPs) in myoblasts in vitro. Muscle homing peptide M12 is covalently conjugated to PLGA-PEG NPs via the N-terminal α-amino groups of peptides using the N-hydroxysuccinimide ester reaction .
loading...
    loading...
Cat. No.: HY-156829B
PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 7:1) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors. The gelation temperature varies with concentration. The gelation temperature varies with the concentration; the higher the concentration, the lower the gelation temperature .
loading...
    loading...
Cat. No.: HY-156829I
PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (15% solution) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (15% solution) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors . The gelation temperature varies with the concentration; the higher the concentration, the lower the gelation temperature.
loading...
    loading...
Cat. No.: HY-148775A
CAS No.: 743423-15-6
MPEG-PLGA (21500-26500) is a biodegradable amphipathic polymeric nanocarrier of poly (lactic-co-glycolic acid)-block-poly (ethylene glycol) (PLGA-PEG-Mal) that allows covalent modification of functional molecules. MPEG-PLGA (21500-26500) modified with Angiopep-2 can cross the blood-brain barrier and exhibits targeting selectivity for glioblastoma cells. MPEG-PLGA (21500-26500) can capture tumor-derived protein antigens, and exerts immunomodulatory effects when conjugated with anti-OX40 antibody; when used in combination with A2-CL/Dbait nanoparticles and radiotherapy, it prolongs survival time and reduces tumor volume in glioblastoma mouse models. MPEG-PLGA (21500-26500) can be used for studies related to bacterial wound infections and glioblastoma .
loading...
    loading...
Cat. No.: HY-145396
Purity:  ≥98.0%
PLGA-PEG-NH2 is a material to synthesis nanomicelles. PLGA-PEG-NH2 nanomicelle is an efficient delivery system of Irinotecan for targeted colorectal cancer and hepatocellular carcinoma .
loading...
    loading...
Cat. No.: HY-144012H
CAS No.: 474922-84-4
Synonyms: 16:0 PEG5000 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] ammonium
DPPE-PEG5000 (16:0 PEG5000 PE) is a polymer-lipid conjugate and LipoParticle stabilizer with a PEG chain of 5,000 g/mol molecular weight attached to its polar head, and it can be internalized by biological membranes. DPPE-PEG5000 enables LipoParticle to maintain colloidal stability after 20-fold dilution in PBS or cell culture medium, and prevents aggregate formation during lyophilization and rehydration. DPPE-PEG5000 helps enhance the non-cytotoxic property of LipoParticle formulations against human osteoblasts. DPPE-PEG5000 serves as a PEG lipid functional end group for synthesizing liposomes (LPs), is used in the design of conjugated polymer nanoparticles, and applies to research related to bone and joint infections .
loading...
    loading...
Cat. No.: HY-156829J
PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (20% solution) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (20% solution) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors. The gelation temperature varies with the concentration; the higher the concentration, the lower the gelation temperature .
loading...
    loading...
Cat. No.: HY-156829A
Research Areas:  

Cancer

PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1) is a matrix materia, with lactic acid (LA):glycolic acid (GA) = 15:1, that acts as anti-cancer drug delivery. PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1) can improve a drug's bioavailability, efficacy, water solubility, drug encapsulation efficiency, sustained drug release, and to minimize undesirable toxicity .
loading...
    loading...
Cat. No.: HY-168943
PLGA nanoparticles, 100nm, are biodegradable tumor-targeting nanocarriers that can serve as drug delivery enhancers and multidrug resistance inhibitors. PLGA nanoparticles, 100nm, passively enriched through the EPR effect and actively targeted via ligand-mediated endocytosis, can encapsulate various antitumor active molecules. PLGA nanoparticles, 100nm can specifically recognize multiple types of tumor cells and improve cellular uptake, cytotoxicity and antiproliferative effects after modification with ligands such as transferrin, folic acid, and RGD. PLGA nanoparticles, 100nm can encapsulate various therapeutic drugs and can be surface modified to achieve targeting, imaging, and prolonged circulation time, making them suitable for cancer-related research .
loading...
    loading...
Cat. No.: HY-P10427
DV1 is a CXCR4 inhibitor with anti-proteolytic properties that specifically blocks the binding of SDF-1α to its receptor. DV1 inhibits the migration of breast cancer cells and enables the targeted delivery of avidin-PLGA nanoparticles to CXCR4-expressing cancer cells. DV1 not only effectively suppresses the progression of metastatic breast cancer in mouse models, but also preferentially accumulates in brain tumor tissues rather than normal brain tissues, showing potential for inhibiting intracranial tumor metastasis. As a humoral immune stimulant, DV1 induces the production of specific IgG, neutralizing antibodies and cellular immune responses, thereby providing the host with protection against lethal challenges. DV1 has been applied to studies on CXCR4-expressing cancers, glioblastoma, dengue fever and other related diseases .
loading...
    loading...